20 assets in Bone Marrow Failure Syndrome

Therapeutic assets addressing Bone Marrow Failure Syndrome, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Fludarabine Bone Marrow Failure Syndrome	Fred Hutchinson Cancer Center	P2/3	BBB (73)
Cyclophosphamide Bone Marrow Failure Syndrome	Memorial Sloan Kettering Cancer Center	P2/3	BBB (72)
Thiotepa Bone Marrow Failure Syndrome	Fred Hutchinson Cancer Center	P2	BB (70)
Alemtuzumab Bone Marrow Failure Syndrome	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P2/3	BB (69)
Busulfanum Bone Marrow Failure Syndrome	Memorial Sloan Kettering Cancer Center	P2/3	BB (69)
Melphalan Bone Marrow Failure Syndrome	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P2	B (63)
Treosulfan Bone Marrow Failure Syndrome	Fred Hutchinson Cancer Center	P2	B (62)
Tacrolimus Bone Marrow Failure Syndrome	Fred Hutchinson Cancer Center	P2	B (61)
Anti-Human T-Lymphocyte Immunoglobulin, Rabbit Bone Marrow Failure Syndrome	M.D. Anderson Cancer Center	P2	B (60)
Cyclosporin A Bone Marrow Failure Syndrome	Memorial Sloan Kettering Cancer Center	P2	B (60)
Methotrexate Bone Marrow Failure Syndrome	Fred Hutchinson Cancer Center	P2	B (60)
Clofarabine Bone Marrow Failure Syndrome	Memorial Sloan Kettering Cancer Center	P2	CCC (53)
Decitabine Bone Marrow Failure Syndrome	Franziska Wachter	P2	CCC (53)
Hpc, Cord Blood Bone Marrow Failure Syndrome	Memorial Sloan Kettering Cancer Center	P2	CCC (53)
Hydroxyurea Bone Marrow Failure Syndrome	Paul Szabolcs	P2	CCC (53)
Nivestim Bone Marrow Failure Syndrome	Franziska Wachter	P2	CCC (53)
Pbsc Bone Marrow Failure Syndrome	Children's Hospital Medical Center, Cincinnati	P2	CCC (53)
Rituximab Bone Marrow Failure Syndrome	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Cytokine-Treated Veto Cells Bone Marrow Failure Syndrome	M.D. Anderson Cancer Center	P1/2	CCC (48)
Lapine T-Lymphocyte Immune Globulin Bone Marrow Failure Syndrome	Fred Hutchinson Cancer Center	P2	CCC (48)